1 January 2025 in Journal of Nanotechnology
Circulating tumor cells (CTCs) are tumor cells released from primary, metastatic, or recurrent tumors into the peripheral blood and responsible for metastasis. They are also useful as a biomarker for cancer, influencing researchers to focus on early detection, enumeration, and isolation of CTCs due to their demonstrated substantial advantages in clinical theragnostic. Detection and isolation of CTCs are particularly challenging because of their extreme rarity and heterogeneity. Although new CTC enrichment and detection techniques have been continuously developed in recent years, enabling deeper analysis of CTC biology and clinical significance, none have yet achieved the “gold” standard. Even the FDA‐approved CellSearch™ suffers from low capture accuracy, high expense, and time consumption. Nowadays, liquid biopsy has become a more convenient and noninvasive method than traditional tissue biopsy in cancer patient management. It is used to develop predictive biomarkers, in addition to prognostication. In a broad spectrum, CTC detection methods can be categorized as label‐dependent (based on positive enrichment using cell surface markers such as epithelial cell adhesion molecule or EpCAM) and label‐independent (based on negative enrichment, considering size or other differential biophysical properties of CTCs). CTCs have provided critical insights into the metastasis process and will continue to do so, potentially leading to the creation of a brand‐new cancer treatment system. In this review article, we provide an overview of the most modern methods for CTC detection and isolation, along with their significance in cancer management. The review also outlines further prospects for advancements in the field. Trial Registration: ClinicalTrials.gov identifier: NCT04556916, NCT03511859, NCT02380196, and NCT05127096
1 May 2012 in Transplantation Proceedings
1 September 2021 in Annals of Oncology
19 November 2025 in Archives of Pharmacal Research
1 June 2021 in Cancer Management and Research
Purpose: Blood loss may be corrected with red blood cell transfusion, but may ultimately contribute to negative impacts. This study was a retrospective analysis to assess the impact of perioperative blood transfusion on hospital stay days in liver cancer patients. Methods: We retrospectively examined data from patients with primary liver cancer who underwent curative resection. Patients were divided into perioperative blood transfusion (PBT) and non-PBT groups. Data were given as means and SDs for continuous variables and as counts and percentage for categorical variables. The correlation between blood transfusion and hospital stay days was analyzed by Fisher’s exact test. Multivariable logistic regression analyses were used to identify independent predictors of length of hospital stays. Results: Totally 206/1031 patients (20.3%) were given perioperative transfusion. The mean length of hospital stay was 17.8 days in PBT and 13.9 days in non-PBT groups. Our multivariable logistic regression showed transfusion, total bilirubin, indirect bilirubin, and the ratio of albumin to bilirubin were all indicators of the length of hospital stay days. Perioperative transfusion was also associated with prolonged length of hospital stays (95% CI: 0.395– 0.811, p = 0.002). Transfusion also affected intrinsic coagulation factors (activated partial thromboplastin time, fibrinogen, platelet), inflammatory index (neutrocyte to lymphocyte ratio, monocyte), albumin and bilirubin levels. Conclusion: Perioperative transfusion of blood was associated with a significantly increased length of hospital stays probably via changing intrinsic coagulation and inflammatory factors and bilirubin levels in plasma.